Apertura Gene Therapy Secures $67 Million in Series A Funding for Next-Generation Genetic Medicine Innovations

Apertura Gene Therapy is thrilled to announce a significant funding round, successfully raising $67 million to advance its groundbreaking work in the field of gene therapy. This funding comes at a crucial time as the company continues to pioneer innovative next-generation adeno-associated virus (AAV) gene therapies aimed at treating debilitating diseases that currently have limited therapeutic options. Founded on cutting-edge technologies developed at the Broad Institute and Harvard University, Apertura is uniquely positioned at the forefront of genetic medicine innovation. By engineering capsids, regulatory elements, and payloads concurrently, the company is overcoming existing limitations in genetic delivery, thereby unlocking new possibilities for patient care. The support of esteemed investors, including Deerfield Management Company, underscores confidence in Apertura’s mission and its potential to transform lives through tailored gene therapies. The funding will be instrumental in accelerating Apertura's research and development efforts, facilitating preclinical and clinical trials, and ultimately pushing the boundaries of what is achievable in treating genetic disorders. As we continue to cultivate our presence at the Cure in New York City, our team is dedicated to collaborating with leading experts and institutions to bring these life-changing therapies to patients who need them most. At Apertura, we are not just envisioning a future where debilitating diseases are effectively treated; we are working tirelessly to make that future a reality.